Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00041652 | Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer | PHASE1 | COMPLETED | 30 | — | — | Feb 1, 2000 | Jun 1, 2003 | Aug 19, 2021 | 1 | United States |
| NCT00040599 | Safety Study of 90Y-hMN14 to Treat Colorectal Cancer | PHASE1 | COMPLETED | 72 | — | — | Jan 1, 2000 | Jan 1, 2004 | Aug 19, 2021 | 10 | United States, Germany +3 |
| Name | Type | Description |
|---|---|---|
| hMN14 (labetuzumab) | DRUG | - |
Disease Characteristics: * Histologic or cytologic diagnosis or either, colonic, rectal, or breast carcinoma * Measurable lesion diagnosed by CT scan * Recurrent/metastatic disease considered surgically unresectable. Prior/Concurrent Therapy: * Chemotherapy: Patients who either have failed at lea...